Invega: Withdrawal of the application to change the marketing authorisation



On 15 December 2008, Janssen-Cilag International NV officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a change to the marketing authorisation for Invega, to add the treatment of acute manic episodes associated with bipolar I disorder.

  • List item

    Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Invega (PDF/39.82 KB)

    First published: 22/01/2009
    Last updated: 22/01/2009

  • Key facts

    Product number
    Date of issue of market authorisation valid throughout the European Union (if applicable)
    International non-proprietary name (INN) or common name
    • paliperidone
    Active substance
    • paliperidone
    Date of withdrawal
    Company making the application
    Janssen-Cilag International NV
    Withdrawal type

    All documents

    Related information on withdrawals

    The question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the application at the time of the withdrawal, and includes a link to the company's formal withdrawal letter.

    An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 90').

    How useful was this page?

    Add your rating